Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive

Sponsor
ViiV Healthcare (Industry)
Overall Status
Completed
CT.gov ID
NCT03984825
Collaborator
(none)
23
1
1
2.1
10.9

Study Details

Study Description

Brief Summary

This is an open-label, single-sequence, 1-way drug-drug interaction study to investigate the effect of GSK3640254 on the pharmacokinetics of a combination oral contraceptive containing ethinyl estradiol (EE) and levonorgestrel (LNG). Effective contraception for women infected with human immunodeficiency virus (HIV) is important in the prevention of unplanned pregnancies. The study will consist of a screening period of 28 days, check-in (Day -4), a run-in period and a treatment period. During the run-in period, subjects will be administered Portia® (0.03 milligrams [mg] EE/0.15 mg LNG) once daily on Days -3 to -1. Subjects will then be administered Portia once daily on Days 1 to 10 of treatment period A followed by administration of Portia once daily along with GSK3640254 200 mg on Days 11 to 21 of treatment period B. The duration of the study is approximately 8 weeks, including Screening and Run-in. Portia is a registered trademark of Teva Pharmaceuticals USA.

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
23 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Effect of Coadministration of GSK3640254 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Subjects
Actual Study Start Date :
Jun 13, 2019
Actual Primary Completion Date :
Aug 16, 2019
Actual Study Completion Date :
Aug 16, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Portia followed by Portia co-administered with GSK3640254

Subjects will be administered Portia (0.03 mg EE/0.15 mg LNG) once daily on Days -3 to -1 during run-in period and on Days 1 to 10 in treatment period A. Subjects will then receive Portia (0.03 mg EE/0.15 mg LNG) co-administered with GSK3640254 200 mg once daily on Days 11 to 21 in treatment period B.

Drug: GSK3640254
GSK3640254 will be available as a 100 mg capsule. Subjects will be administered 200 mg GSK3640254 once daily via the oral route on Days 11 to 21.

Drug: Portia
Portia will be available in the form of tablets containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel.

Outcome Measures

Primary Outcome Measures

  1. Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing Interval at Steady State (AUC [0-tau]) of EE [Day 10: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 11: 24 hours]

    Blood samples were collected at indicated time points for the analysis of AUC (0-tau) of EE. PK parameters were calculated by standard non-compartmental analysis. The PK population included all participants who underwent plasma PK sampling and had evaluable PK parameters estimated.

  2. Period 2: AUC (0-tau) of EE [Day 21: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 and 24 hours post dose]

    Blood samples were collected at indicated time points for the analysis of AUC (0-tau) of EE. PK parameters were calculated by standard non-compartmental analysis.

  3. Period 1:AUC (0-tau) of LNG [Day 10: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 11: 24 hours]

    Blood samples were collected at indicated time points for the analysis of AUC (0-tau) of LNG. PK parameters were calculated by standard non-compartmental analysis.

  4. Period 2: AUC (0-tau) of LNG [Day 21: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 and 24 hours post dose]

    Blood samples were collected at indicated time points for the analysis of AUC (0-tau) of LNG. PK parameters were calculated by standard non-compartmental analysis.

  5. Period 1: Maximum Observed Concentration (Cmax) and Plasma Concentration at the End of the Dosing Interval (Ctau) of EE [Day 10: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 11: 24 hours]

    Blood samples were collected at indicated time points for the analysis of Cmax and Ctau of EE. PK parameters were calculated by standard non-compartmental analysis.

  6. Period 2: Cmax and Ctau of EE [Day 21: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 and 24 hours]

    Blood samples were collected at indicated time points for the analysis of Cmax and Ctau of EE. PK parameters were calculated by standard non-compartmental analysis.

  7. Period 1:Cmax and Ctau of LNG [Day 10: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 11: 24 hours]

    Blood samples were collected at indicated time points for the analysis of Cmax and Ctau of LNG. PK parameters were calculated by standard non-compartmental analysis.

  8. Period 2: Cmax and Ctau of LNG [Day 21: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 and 24 hours post dose]

    Blood samples were collected at indicated time points for the analysis of Cmax and Ctau of LNG. PK parameters were calculated by standard non-compartmental analysis.

Secondary Outcome Measures

  1. Period 1: Effect of GSK3640254 on PD of EE/LNG- Serum Progesterone Level [At Day 1 and Day 10]

    Serum samples were collected for the analysis of progesterone concentration levels when GSK3640254 is co-administered with EE/LNG. PD concentration Population comprised of all participants who underwent plasma PD sampling and had evaluable PD assay results.

  2. Period 2: Effect of GSK3640254 on PD of EE/LNG- Serum Progesterone Level [At Days 11, 21 and 22]

    Serum samples were collected for the analysis progesterone concentration levels when GSK3640254 is co-administered with EE/LNG.

  3. Period 1: Absolute Values of Effect of GSK3640254 on Luteinizing Hormone (LH) and Follicle-stimulating Hormone (FSH) [At Day 1 and Day 10]

    Serum samples were collected for the analysis of effect of GSK3640254 on LH and FSH.

  4. Period 2: Absolute Values of Effect of GSK3640254 on LH and FSH [At Days 11, 21 and 22]

    Serum samples were collected for the analysis of effect of GSK3640254 on LH and FSH.

  5. Period 2: AUC (0-tau) of GSK3640254 [Day 21: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8 and 12 and 24 hours post dose]

    Blood samples were collected at indicated time points for the analysis of AUC (0-tau) of GSK3640254. PK parameters were calculated by standard non-compartmental analysis.

  6. Period 2: Cmax and Ctau of GSK3640254 [Day 21: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8 and 12 and 24 hours post dose]

    Blood samples were collected at indicated time points for the analysis of Cmax and Ctau of GSK3640254. PK parameters were calculated by standard non-compartmental analysis.

  7. Period 2: Apparent Terminal Phase Half-life (t1/2) of GSK3640254 [Day 21: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8 and 12 hours; Day 22: 24 hours; Day 23: 48 hours; Day 24: 72 hours and Day 25: 96 hours]

    Blood samples were collected at indicated time points for the analysis of t1/2 of GSK3640254. PK parameters were calculated by standard non-compartmental analysis.

  8. Period 2: Time of Maximum Observed Concentration (Tmax) of GSK3640254 [Day 21: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8 and 12 and 24 hours post dose]

    Blood samples were collected at indicated time points for the analysis of Tmax of GSK3640254. PK parameters were calculated by standard non-compartmental analysis.

  9. Period 1: t1/2 of EE [Day 10: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 11: 24 hours]

    Blood samples were collected at indicated time points for the analysis of t1/2 of EE. PK parameters were calculated by standard non-compartmental analysis.

  10. Period 2: t1/2 of EE [Day 21: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 22: 24 hours; Day 23: 48 hours and Day 24: 72 hours]

    Blood samples were collected at indicated time points for the analysis of t1/2 of EE. PK parameters were calculated by standard non-compartmental analysis.

  11. Period 1: Tmax of EE [Day 10: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 11: 24 hours]

    Blood samples were collected at indicated time points for the analysis of Tmax of EE. PK parameters were calculated by standard non-compartmental analysis.

  12. Period 2: Tmax of EE [Day 21: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 22: 24 hours; Day 23: 48 hours and Day 24: 72 hours]

    Blood samples were collected at indicated time points for the analysis of Tmax of EE. PK parameters were calculated by standard non-compartmental analysis.

  13. Period 1: t1/2 of LNG [Day 10: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 11: 24 hours]

    Blood samples were collected at indicated time points for the analysis of t1/2 of LNG. PK parameters were calculated by standard non-compartmental analysis.

  14. Period 2: t1/2 of LNG [Day 21: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours; Day 22: 24 hours; Day 23: 48 hours and Day 24: 72 hours]

    Blood samples were collected at indicated time points for the analysis of t1/2 of LNG. PK parameters were calculated by standard non-compartmental analysis.

  15. Period 1: Tmax of LNG [Day 10: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 11: 24 hours]

    Blood samples were collected at indicated time points for the analysis of Tmax of LNG. PK parameters were calculated by standard non-compartmental analysis.

  16. Period 2: Tmax of LNG [Day 21: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours; Day 22: 24 hours; Day 23: 48 hours and Day 24: 72 hours]

    Blood samples were collected at indicated time points for the analysis of Tmax of LNG. PK parameters were calculated by standard non-compartmental analysis.

  17. Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAE) (Treatment Period) [Up to Day 25]

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. Safety Population comprised of all participants who received at least one dose of study medication.

  18. Number of Participants With Non-SAEs and SAE (Run-in Period) [From Day -3 to Day -1]

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before.

  19. Period 1: Change From Baseline in Clinical Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium and Blood Urea Nitrogen (BUN) [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and BUN. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  20. Period 2: Change From Baseline in Clinical Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium and BUN [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and BUN. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  21. Period 1: Change From Baseline in Clinical Chemistry Parameters: Plasma Albumin, Globulin and Protein [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including plasma albumin, globulin and protein. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  22. Period 2: Change From Baseline in Clinical Chemistry Parameters: Plasma Albumin, Globulin and Protein [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including plasma albumin, globulin and protein. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  23. Period 1: Change From Baseline in Clinical Chemistry Parameters: Plasma Amylase and Lipase [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including plasma amylase and lipase. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  24. Period 2: Change From Baseline in Clinical Chemistry Parameters: Plasma Amylase and Lipase [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including plasma amylase and lipase. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  25. Period 1: Change From Baseline in Clinical Chemistry Parameters: Plasma Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Gamma Glutamyl Transferase (GGT) [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Plasma creatine kinase, lactate dehydrogenase, ALT, ALP, AST and GGT. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  26. Period 2: Change From Baseline in Clinical Chemistry Parameters: Plasma Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST and GGT [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Plasma creatine kinase, lactate dehydrogenase, ALT, ALP, AST and GGT. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  27. Period 1: Change From Baseline in Clinical Chemistry Parameters: Plasma Urate, Creatinine, Total Bilirubin and Direct Bilirubin [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Plasma urate, creatinine, total bilirubin and direct bilirubin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  28. Period 2: Change From Baseline in Clinical Chemistry Parameters: Plasma Urate, Creatinine, Total Bilirubin and Direct Bilirubin [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Plasma urate, creatinine, total bilirubin and direct bilirubin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  29. Period 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of hematology parameters including Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  30. Period 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of hematology parameters including Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  31. Period 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes mean corpuscular hemoglobin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  32. Period 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes mean corpuscular hemoglobin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  33. Period 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes mean corpuscular volume. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  34. Period 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes mean corpuscular volume. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  35. Period 1: Change From Baseline in Hematology Parameter: Erythrocytes [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  36. Period 2: Change From Baseline in Hematology Parameter: Erythrocytes [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  37. Period 1: Change From Baseline in Hematology Parameter: Hematocrit [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of hematology parameter hematocrit. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  38. Period 2: Change From Baseline in Hematology Parameter: Hematocrit [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of hematology parameter hematocrit. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  39. Period 1: Change From Baseline in Hematology Parameter: Hemoglobin [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of hematology parameter hemoglobin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  40. Period 2: Change From Baseline in Hematology Parameter: Hemoglobin [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of hematology parameter hemoglobin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  41. Period 1: Change From Baseline in Urine Concentration: Urine Specific Gravity [Baseline (Day 1, Pre-dose) and at Day 10]

    Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  42. Period 2: Change From Baseline in Urine Concentration: Urine Specific Gravity [Baseline (Day 10) and at Days 21 and 24]

    Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  43. Period 1: Change From Baseline in Urine Concentration: Urine Urobilinogen [Baseline (Day 1, Pre-dose) and at Day 10]

    Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  44. Period 2: Change From Baseline in Urine Concentration: Urine Urobilinogen [Baseline (Day 10) and at Days 21 and 24]

    Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  45. Period 1: Change From Baseline in Urine Concentration: Urine Potential of Hydrogen (pH) [Baseline (Day 1, Pre-dose) and at Day 10]

    Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  46. Period 2: Change From Baseline in Urine Concentration: Urine pH [Baseline (Day 10) and at Days 21 and 24]

    Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  47. Period 1: Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate [Baseline (Day 1, Pre-dose) and at Day 10]

    Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  48. Period 2: Change From Baseline in ECG Mean Heart Rate [Baseline (Day 11, Pre-dose) and at Day 11: 2, 4, 6 hours, Day 15: 2, 4, 6 hours, Day 21 and 24]

    Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline is defined as the average of the triplicate predose assessments on Day 11. Change from Baseline was defined as post-dose visit value minus Baseline value.

  49. Period 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF) Interval, and Bazett QT Correction Formula (QTcB) Interval [Baseline (Day 1, Pre-dose) and at Day 10]

    Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR interval, QRS duration, QT Interval, QTcF Interval and QTcB interval. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  50. Period 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF and QTcB Interval [Baseline (Day 11, Pre-dose) and at Day 11: 2, 4, 6 hours, Day 15: 2, 4, 6 hours, Day 21 and 24]

    Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline is defined as the average of the triplicate predose assessments on Day 11. Change from Baseline was defined as post-dose visit value minus Baseline value.

  51. Period 1: Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) [Baseline (Day 1, Pre-dose) and at Day 10]

    SBP and DBP were assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline is defined as the average of the triplicate pre-dose assessments. Change from Baseline was defined as post-dose visit value minus Baseline value.

  52. Period 2: Change From Baseline in Vital Signs: SBP and DBP [Baseline (Day 11, Pre-dose) and at Days 15, 21 and 24]

    SBP and DBP were assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline is defined as as the average of the triplicate pre-dose assessments. Change from Baseline was defined as post-dose visit value minus Baseline value.

  53. Period 1: Change From Baseline in Pulse Rate [Baseline (Day 1, Pre-dose) and at Day 10]

    Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline is defined as the average of the triplicate predose assessments. Change from Baseline was defined as post-dose visit value minus Baseline value.

  54. Period 2: Change From Baseline in Pulse Rate [Baseline (Day 11, Pre-dose) and at Days 15, 21 and 24]

    Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline is defined as the average of the triplicate predose assessments. Change from Baseline was defined as post-dose visit value minus Baseline value.

  55. Period 1: Change From Baseline in Respiratory Rate [Baseline (Day 1, Pre-dose) and at Day 10]

    Respiratory rate was assessed at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  56. Period 2: Change From Baseline in Respiratory Rate [Baseline (Day 11, Pre-dose) and at Days 15, 21 and 24]

    Respiratory rate was assessed at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  57. Period 1: Change From Baseline in Temperature [Baseline (Day 1, Pre-dose) and at Day 10]

    Temperature was assessed at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  58. Period 2: Change From Baseline in Temperature [Baseline (Day 11, Pre-dose) and at Days 15, 21 and 24]

    Temperature was assessed at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.

  59. Period 1: Absolute Values of Clinical Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium and BUN [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and BUN. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  60. Period 2: Absolute Values of Clinical Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium and BUN [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and BUN. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  61. Period 1: Absolute Values of Clinical Chemistry Parameters: Plasma Albumin, Globulin and Protein [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including plasma albumin, globulin and protein. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  62. Period 2: Absolute Values of Clinical Chemistry Parameters: Plasma Albumin, Globulin and Protein [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including plasma albumin, globulin and protein. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  63. Period 1: Absolute Values of Clinical Chemistry Parameters: Plasma Amylase and Lipase [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including plasma amylase and lipase. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  64. Period 2: Absolute Values of Clinical Chemistry Parameters: Plasma Amylase and Lipase [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including plasma amylase and lipase. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  65. Period 1: Absolute Values of Clinical Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST and GGT [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including creatine kinase, lactate dehydrogenase, ALT, ALP, AST and GGT. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  66. Period 2: Absolute Values of Clinical Chemistry Parameters: Plasma Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST and GGT [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Plasma creatine kinase, lactate dehydrogenase, ALT, ALP, AST and GGT. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  67. Period 1: Absolute Values of Clinical Chemistry Parameters: Urate, Creatinine, Total Bilirubin and Direct Bilirubin [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Plasma urate, creatinine, total bilirubin and direct bilirubin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  68. Period 2: Absolute Values of Clinical Chemistry Parameters: Plasma Urate, Creatinine, Total Bilirubin and Direct Bilirubin [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Plasma urate, creatinine, total bilirubin and direct bilirubin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  69. Period 1: Absolute Values of Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of hematology parameters including Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  70. Period 2: Absolute Values of Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of hematology parameters including Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  71. Period 1: Absolute Values of Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes mean corpuscular hemoglobin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  72. Period 2: Absolute Values of Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes mean corpuscular hemoglobin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  73. Period 1: Absolute Values of Hematology Parameter: Erythrocytes Mean Corpuscular Volume [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes mean corpuscular volume. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  74. Period 2: Absolute Values of Hematology Parameter: Erythrocytes Mean Corpuscular Volume [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes mean corpuscular volume. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  75. Period 1: Absolute Values of Hematology Parameter: Erythrocytes [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  76. Period 2: Absolute Values of Hematology Parameter: Erythrocytes [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  77. Period 1: Absolute Values of Hematology Parameter: Hematocrit [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of hematology parameter hematocrit. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  78. Period 2: Absolute Values of Hematology Parameter: Hematocrit [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of hematology parameter hematocrit. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  79. Period 1: Absolute Values of Hematology Parameter: Hemoglobin [Baseline (Day 1, Pre-dose) and at Day 10]

    Blood samples were collected at indicated time points for the analysis of hematology parameter hemoglobin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  80. Period 2: Absolute Values of Hematology Parameter: Hemoglobin [Baseline (Day 10) and at Days 21 and 24]

    Blood samples were collected at indicated time points for the analysis of hematology parameter hemoglobin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  81. Period 1: Absolute Values of Urine Concentration: Urine Specific Gravity [Baseline (Day 1, Pre-dose) and at Day 10]

    Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  82. Period 2: Absolute Values of Urine Concentration: Urine Specific Gravity [Baseline (Day 10) and at Days 21 and 24]

    Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  83. Period 1: Absolute Values of Urine Concentration: Urine Urobilinogen [Baseline (Day 1, Pre-dose) and at Day 10]

    Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  84. Period 2: Absolute Values of Urine Concentration: Urine Urobilinogen [Baseline (Day 10) and at Days 21 and 24]

    Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  85. Period 1: Absolute Values of Urine Concentration: Urine pH [Baseline (Day 1, Pre-dose) and at Day 10]

    Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  86. Period 2: Absolute Values of Urine Concentration: Urine pH [Baseline (Day 10) and at Days 21 and 24]

    Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  87. Period 1: Number of Participants With Abnormal Urinalysis Parameters Using Dipstick Method. [Baseline (Day 1, Pre-dose) and at Day 10]

    The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters (ketones, glucose, bilirubin, occult blood, nitrite and blood protein) can be read as positive, trace, 1+, 2+, 3+ and 4+ indicating proportional concentrations in the urine sample. Only participants with abnormal findings for urinalysis at any visit has been presented.

  88. Period 2: Number of Participants With Abnormal Urinalysis Parameters Using Dipstick Method. [Baseline (Day 10) and at Days 21 and 24]

    The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters (ketones, glucose, bilirubin, occult blood, nitrite and blood protein) can be read as positive, trace, 1+, 2+, 3+ and 4+ indicating proportional concentrations in the urine sample. Only participants with abnormal findings for urinalysis at any visit has been presented.

  89. Period 1: Absolute Values of ECG Mean Heart Rate [Baseline (Day 1, Pre-dose) and at Day 10]

    Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  90. Period 2: Absolute Values of ECG Mean Heart Rate [Baseline (Day 11, Pre-dose) and at Day 11: 2, 4, 6 hours, Day 15: 2, 4, 6 hours, Day 21 and 24]

    Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline is defined as the average of the triplicate predose assessments on Day 11.

  91. Period 1: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval, and QTcB Interval [Baseline (Day 1, Pre-dose) and at Day 10]

    Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR interval, QRS duration, QT Interval, QTcF Interval and QTcB interval. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  92. Period 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF and QTcB Interval [Baseline (Day 11, Pre-dose) and at Day 11- 2, 4, 6 hours, Day 15- 2, 4, 6 hours, Day 21 and 24]

    Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR Interval, QRS Duration, QT Interval, QTcF and QTcB Interval. Baseline is defined as the average of the triplicate predose assessments on Day 11.

  93. Period 1: Absolute Values of Vital Signs: SBP and DBP [Baseline (Day 1, Pre-dose) and at Day 10]

    SBP and DBP were assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline is defined as the average of the triplicate predose assessments on Day 11.

  94. Period 2: Absolute Values of Vital Signs: SBP and DBP [Baseline (Day 11, Pre-dose) and at Days 15, 21 and 24]

    SBP and DBP were assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  95. Period 1: Absolute Values of Pulse Rate [Baseline (Day 1, Pre-dose) and at Day 10]

    Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  96. Period 2: Absolute Values of Pulse Rate [Baseline (Day 11, Pre-dose) and at Days 15, 21 and 24]

    Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  97. Period 1: Absolute Values of Respiratory Rate [Baseline (Day 1, Pre-dose) and at Day 10]

    Respiratory rate was assessed indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  98. Period 2: Absolute Values of Respiratory Rate [Baseline (Day 11, Pre-dose) and at Days 15, 21 and 24]

    Respiratory rate was assessed indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  99. Period 1: Absolute Values of Temperature [Baseline (Day 1, Pre-dose) and at Day 10]

    Temperature was assessed at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

  100. Period 2: Absolute Values of Temperature [Baseline (Day 11, Pre-dose) and at Days 15, 21 and 24]

    Temperature was assessed at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Subject must be 18 to 50 years of age inclusive, at the time of signing the informed consent.

  • Subjects who are healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring (history and ECG).

  • Body weight >=45.0 kilograms (kg) (99 pounds [lbs]) and body mass index (BMI) within the range 18.5 to 31.0 kilograms per meter square (kg/m^2) (inclusive).

  • Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

  • Female subjects will be included.

  • Subject must not be pregnant or breastfeeding.

  • Subject is a woman of childbearing potential (WOCBP) with intact ovarian function, as determined by medical history. Subjects must use Portia for the duration of the run-in and treatment periods.

  • WOCBP must have been on an acceptable form of contraceptive for at least 28 days prior to start of study intervention. Acceptable forms of contraception prior to study intervention include the following: Intrauterine device or intrauterine system; Combined estrogen and progestogen oral contraceptive; Contraceptive vaginal ring; Percutaneous contraceptive patches (if used, the patch must be removed during study participation); Bilateral tubal occlusion; Male partner sterilization with documentation of azoospermia prior to the female subject's entry into the study, and this male is the sole partner for that subject. The documentation on male sterility can come from the site personnel's review of subject's medical records, medical examination and/or semen analysis, or medical history interview provided by her or her partner.; Sexual abstinence.

  • Subjects who have been on a stable regimen of an oral contraceptive for at least 3 consecutive months must be without evidence of breakthrough bleeding or spotting.

  • Subjects who have been taking oral contraceptives should continue their current regimen until check-in to the clinic for the run-in period. Subjects not currently taking an oral contraceptive are eligible, provided all other eligibility criteria are met.

  • Subjects may proceed to the treatment period provided the toxicity profile during the run-in period with Portia is acceptable in the opinion of the investigator.

  • Subjects must agree to use an additional method of contraception from the following list of contraceptive methods for the run-in period, treatment period, and for 28 days after the last dose of study intervention: Non hormonal Intrauterine device; Bilateral tubal occlusion; Male partner sterilization with documentation of azoospermia prior to the female subject's entry into the study, and this male is the sole partner for that subject. The documentation on male sterility can come from the site personnel's review of subject's medical records, medical examination and/or semen analysis, or medical history interview provided by her or her partner.; Sexual abstinence. For the 28 days after study exit, women may resume oral contraceptives but double barrier methods (a combination of male condom with either cervical cap, diaphragm, or sponge with spermicide) must be used in addition.

  • Women of childbearing potential must have a negative highly sensitive serum pregnancy test on Day -4 and Day -1.

  • Additional requirements for pregnancy testing during and after study intervention as outlined in protocol.

  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form and protocol.

Exclusion Criteria:
  • History of jaundice associated with taking oral contraceptives or with pregnancy.

  • History of clinically significant irregular bleeding while taking oral contraceptives.

  • History of past deep venous thrombosis, pulmonary embolism, stroke, transient ischemic attack, phlebitis, or migraine headaches with prolonged aura.

  • History of cerebrovascular or coronary artery disease.

  • History of retinal vascular lesions.

  • History of carcinoma of the breast, endometrium, or other known estrogen-dependent neoplasia.

  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).

  • A pre-existing condition interfering with normal gastrointestinal (GI) anatomy or motility (e.g., gastroesophageal reflux disease, gastric ulcers, gastritis), hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs or render the subject unable to take oral study intervention.

  • Any history of significant underlying psychiatric disorder, including, but not limited to, schizophrenia, bipolar disorder with or without psychotic symptoms, other psychotic disorders, or schizotypal (personality) disorder.

  • Any history of major depressive disorder with or without suicidal features, or anxiety disorders that required medical intervention (pharmacologic or not) such as hospitalization or other inpatient treatment and/or chronic (>6 months) outpatient treatment. Subjects with other conditions such as adjustment disorder or dysthymia that have required shorter term medical therapy (<6 months) without inpatient treatment and are currently well-controlled clinically or resolved may be considered for entry after discussion and agreement with the ViiV Healthcare/GlaxoSmithKline (GSK) Medical Monitor.

  • Any pre-existing physical or other psychiatric condition (including alcohol or drug abuse), which, in the opinion of the investigator (with or without psychiatric evaluation), could interfere with the subject's ability to comply with the dosing schedule and protocol evaluations or which might compromise the safety of the subject.

  • Medical history of cardiac arrhythmias, prior myocardial infarction in the past 3 months, or cardiac disease or a family or personal history of long QT syndrome.

  • Presence of hepatitis B surface antigen at Screening or within 3 months prior to starting study intervention.

  • Positive hepatitis C antibody test result at Screening or within 3 months prior to starting study intervention AND positive on reflex to hepatitis C ribonucleic acid (RNA).

  • Positive HIV-1 and -2 antigen/antibody immunoassay at Screening.

  • ALT >1.5 times upper limit of normal (ULN). A single repeat of ALT is allowed within a single screening period to determine eligibility.

  • Bilirubin >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).

  • Any acute laboratory abnormality at Screening which, in the opinion of the investigator, should preclude participation in the study of an investigational compound.

  • Any Grade 2 to 4 laboratory abnormality at Screening, with the exception of creatine phosphokinase (CPK) and lipid abnormalities (e.g., total cholesterol, triglycerides, etc), and ALT (described above), will exclude a subject from the study unless the investigator can provide a compelling explanation for the laboratory result(s) and has the assent of the sponsor. A single repeat of any laboratory abnormality is allowed within a single screening period to determine eligibility.

  • A positive test result for drugs of abuse (including marijuana), alcohol, or cotinine (indicating active current smoking) at Screening or before the first dose of study intervention.

  • Unable to refrain from the use of prescription or nonprescription drugs including vitamins, herbal and dietary supplements (including St John's wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study intervention and for the duration of the study (acetaminophen/paracetamol at doses of <=2 grams/day and hydrocortisone cream 1% are permitted for use any time during the study).

  • Treatment with any vaccine within 30 days prior to receiving study intervention.

  • Unwillingness to abstain from excessive consumption of any food or drink containing grapefruit and grapefruit juice, Seville oranges, blood oranges, or pomelos or their fruit juices within 7 days prior to the first dose of study intervention(s) until the end of the study.

  • Participation in another concurrent clinical study or prior clinical study (with the exception of imaging trials) prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).

  • Where participation in the study would result in donation of blood or blood products in excess of 500 milliliters (mL) within 56 days.

  • Any positive (abnormal) response confirmed by the investigator on a screening clinician- or qualified designee-administered Columbia Suicide Severity Rating Scale (C-SSRS).

  • Any significant arrhythmia or ECG finding (e.g., symptomatic bradycardia, non-sustained or sustained atrial arrhythmias, non-sustained or sustained ventricular tachycardia, second-degree atrioventricular block Mobitz Type II, or third-degree atrioventricular block) which, in the opinion of the investigator or ViiV Healthcare/GSK Medical Monitor, will interfere with the safety for the individual subject.

  • Exclusion criteria for screening ECG (a single repeat is allowed for eligibility determination): heart rate-<50 or >100 beats per minute and QTcF->450 milliseconds.

  • History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of >14 units. One unit is equivalent to 8 g of alcohol: a half-pint (equivalent to 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.

  • Unable to refrain from tobacco- or nicotine-containing within 3 months prior to Screening.

  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.

Contacts and Locations

Locations

Site City State Country Postal Code
1 GSK Investigational Site Austin Texas United States 78744

Sponsors and Collaborators

  • ViiV Healthcare

Investigators

  • Study Director: GSK Clinical Trials, ViiV Healthcare

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
ViiV Healthcare
ClinicalTrials.gov Identifier:
NCT03984825
Other Study ID Numbers:
  • 208135
First Posted:
Jun 13, 2019
Last Update Posted:
Aug 27, 2020
Last Verified:
Aug 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by ViiV Healthcare
Additional relevant MeSH terms:

Study Results

Participant Flow

Recruitment Details This was a Phase 1, open-label, fixed-sequence, 1-way drug-drug interaction (DDI) study to assess the Pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability of GSK3640254 and an oral contraceptive containing Ethinyl estradiol/Levonorgestrel (EE/LNG, Portia) when administered alone and in combination in healthy female participants.
Pre-assignment Detail A total of 23 participants were enrolled in the study
Arm/Group Title Portia Followed by Portia + GSK3640254
Arm/Group Description Participants in Run-in period received Portia (0.03 milligram [mg] EE/0.15 mg LNG) once daily (QD) on Day -3 through Day -1. Participants in Treatment Period 1 received Portia (0.3 mg EE/ 0.15 mg LNG) QD on Day 1 through Day 10. In Treatment Period 2 participants received Portia QD co-administered with GSK3640254 200 mg QD on Day 11 through Day 21. There was no washout period between two periods.
Period Title: Run-in Period (Day -3 to -1)
STARTED 23
COMPLETED 23
NOT COMPLETED 0
Period Title: Run-in Period (Day -3 to -1)
STARTED 23
COMPLETED 21
NOT COMPLETED 2
Period Title: Run-in Period (Day -3 to -1)
STARTED 21
COMPLETED 17
NOT COMPLETED 4

Baseline Characteristics

Arm/Group Title Portia Followed by Portia + GSK3640254
Arm/Group Description Participants in Run-in period received Portia (0.03 milligram [mg] EE/0.15 mg LNG) once daily (QD) on Day -3 through Day -1. Participants in Treatment Period 1 received Portia (0.3 mg EE/ 0.15 mg LNG) QD on Day 1 through Day 10. In Treatment Period 2 participants received Portia QD co-administered with GSK3640254 200 mg QD on Day 11 through Day 21. There was no washout period between two periods.
Overall Participants 23
Age (Years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Years]
34.7
(7.82)
Sex: Female, Male (Count of Participants)
Female
23
100%
Male
0
0%
Race/Ethnicity, Customized (Count of Participants)
American Indian or Alaska Native
1
4.3%
Asian-Central/South Asian Heritage
1
4.3%
Black or African American
12
52.2%
White
9
39.1%

Outcome Measures

1. Primary Outcome
Title Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing Interval at Steady State (AUC [0-tau]) of EE
Description Blood samples were collected at indicated time points for the analysis of AUC (0-tau) of EE. PK parameters were calculated by standard non-compartmental analysis. The PK population included all participants who underwent plasma PK sampling and had evaluable PK parameters estimated.
Time Frame Day 10: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 11: 24 hours

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Geometric Mean (Geometric Coefficient of Variation) [Hour*picograms per milliliter]
748.7
(25.2)
2. Primary Outcome
Title Period 2: AUC (0-tau) of EE
Description Blood samples were collected at indicated time points for the analysis of AUC (0-tau) of EE. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 21: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 and 24 hours post dose

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Geometric Mean (Geometric Coefficient of Variation) [Hour*picograms per milliliter]
735.8
(23.6)
3. Primary Outcome
Title Period 1:AUC (0-tau) of LNG
Description Blood samples were collected at indicated time points for the analysis of AUC (0-tau) of LNG. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 10: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 11: 24 hours

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Geometric Mean (Geometric Coefficient of Variation) [Hour*picograms per milliliter]
68682.4
(40.3)
4. Primary Outcome
Title Period 2: AUC (0-tau) of LNG
Description Blood samples were collected at indicated time points for the analysis of AUC (0-tau) of LNG. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 21: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 and 24 hours post dose

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Geometric Mean (Geometric Coefficient of Variation) [Hour*picograms per milliliter]
75412.0
(40.7)
5. Primary Outcome
Title Period 1: Maximum Observed Concentration (Cmax) and Plasma Concentration at the End of the Dosing Interval (Ctau) of EE
Description Blood samples were collected at indicated time points for the analysis of Cmax and Ctau of EE. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 10: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 11: 24 hours

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Cmax
70.01
(34.9)
Ctau
14.83
(32.1)
6. Primary Outcome
Title Period 2: Cmax and Ctau of EE
Description Blood samples were collected at indicated time points for the analysis of Cmax and Ctau of EE. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 21: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 and 24 hours

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Cmax
68.47
(33.3)
Ctau
15.69
(27.8)
7. Primary Outcome
Title Period 1:Cmax and Ctau of LNG
Description Blood samples were collected at indicated time points for the analysis of Cmax and Ctau of LNG. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 10: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 11: 24 hours

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Cmax
5806
(39.3)
Ctau
1870
(49.0)
8. Primary Outcome
Title Period 2: Cmax and Ctau of LNG
Description Blood samples were collected at indicated time points for the analysis of Cmax and Ctau of LNG. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 21: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 and 24 hours post dose

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Cmax
5948
(36.7)
Ctau
2163
(46.6)
9. Secondary Outcome
Title Period 1: Effect of GSK3640254 on PD of EE/LNG- Serum Progesterone Level
Description Serum samples were collected for the analysis of progesterone concentration levels when GSK3640254 is co-administered with EE/LNG. PD concentration Population comprised of all participants who underwent plasma PD sampling and had evaluable PD assay results.
Time Frame At Day 1 and Day 10

Outcome Measure Data

Analysis Population Description
PD concentration Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Day 1
6.103
(5.0947)
Day 10
4.410
(1.5370)
10. Secondary Outcome
Title Period 2: Effect of GSK3640254 on PD of EE/LNG- Serum Progesterone Level
Description Serum samples were collected for the analysis progesterone concentration levels when GSK3640254 is co-administered with EE/LNG.
Time Frame At Days 11, 21 and 22

Outcome Measure Data

Analysis Population Description
PD concentration Population. Only those participants with data available at specified time points has been presented (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Day 11, n=21
3.906
(1.2178)
Day 21, n=17
3.618
(0.9386)
Day 22, n=17
3.988
(1.4316)
11. Secondary Outcome
Title Period 1: Absolute Values of Effect of GSK3640254 on Luteinizing Hormone (LH) and Follicle-stimulating Hormone (FSH)
Description Serum samples were collected for the analysis of effect of GSK3640254 on LH and FSH.
Time Frame At Day 1 and Day 10

Outcome Measure Data

Analysis Population Description
PD concentration Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
LH, Day 1
9.500
(11.0104)
LH, Day 10
2.747
(1.9554)
FSH, Day 1
5.109
(3.7754)
FSH, Day 10
2.215
(1.4567)
12. Secondary Outcome
Title Period 2: Absolute Values of Effect of GSK3640254 on LH and FSH
Description Serum samples were collected for the analysis of effect of GSK3640254 on LH and FSH.
Time Frame At Days 11, 21 and 22

Outcome Measure Data

Analysis Population Description
PD concentration Population. Only those participants with data available at specified time points has been presented (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
LH, Day 11, n=21
2.255
(1.6299)
LH, Day 21, n=17
1.202
(0.6667)
LH, Day 22, n=17
1.287
(0.8298)
FSH, Day 11, n=21
2.162
(1.4388)
FSH, Day 21, n=17
1.535
(0.8285)
FSH, Day 22, n=17
1.638
(1.2380)
13. Secondary Outcome
Title Period 2: AUC (0-tau) of GSK3640254
Description Blood samples were collected at indicated time points for the analysis of AUC (0-tau) of GSK3640254. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 21: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8 and 12 and 24 hours post dose

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Geometric Mean (Geometric Coefficient of Variation) [Hour*micrograms per milliliter]
30.22
(23.1)
14. Secondary Outcome
Title Period 2: Cmax and Ctau of GSK3640254
Description Blood samples were collected at indicated time points for the analysis of Cmax and Ctau of GSK3640254. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 21: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8 and 12 and 24 hours post dose

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Cmax
1.780
(30.4)
Ctau
0.9663
(27.1)
15. Secondary Outcome
Title Period 2: Apparent Terminal Phase Half-life (t1/2) of GSK3640254
Description Blood samples were collected at indicated time points for the analysis of t1/2 of GSK3640254. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 21: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8 and 12 hours; Day 22: 24 hours; Day 23: 48 hours; Day 24: 72 hours and Day 25: 96 hours

Outcome Measure Data

Analysis Population Description
PK Population. Only those participants with data available at specified time points were analyzed.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 14
Geometric Mean (Geometric Coefficient of Variation) [Hours]
25.656
(19.1)
16. Secondary Outcome
Title Period 2: Time of Maximum Observed Concentration (Tmax) of GSK3640254
Description Blood samples were collected at indicated time points for the analysis of Tmax of GSK3640254. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 21: Pre-dose, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8 and 12 and 24 hours post dose

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Median (Full Range) [Hours]
4.500
17. Secondary Outcome
Title Period 1: t1/2 of EE
Description Blood samples were collected at indicated time points for the analysis of t1/2 of EE. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 10: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 11: 24 hours

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Geometric Mean (Geometric Coefficient of Variation) [Hours]
NA
(NA)
18. Secondary Outcome
Title Period 2: t1/2 of EE
Description Blood samples were collected at indicated time points for the analysis of t1/2 of EE. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 21: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 22: 24 hours; Day 23: 48 hours and Day 24: 72 hours

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Geometric Mean (Geometric Coefficient of Variation) [Hours]
20.215
(17.4)
19. Secondary Outcome
Title Period 1: Tmax of EE
Description Blood samples were collected at indicated time points for the analysis of Tmax of EE. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 10: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 11: 24 hours

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Median (Full Range) [Hours]
2.000
20. Secondary Outcome
Title Period 2: Tmax of EE
Description Blood samples were collected at indicated time points for the analysis of Tmax of EE. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 21: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 22: 24 hours; Day 23: 48 hours and Day 24: 72 hours

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Median (Full Range) [Hours]
2.000
21. Secondary Outcome
Title Period 1: t1/2 of LNG
Description Blood samples were collected at indicated time points for the analysis of t1/2 of LNG. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 10: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 11: 24 hours

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Geometric Mean (Geometric Coefficient of Variation) [Hours]
NA
(NA)
22. Secondary Outcome
Title Period 2: t1/2 of LNG
Description Blood samples were collected at indicated time points for the analysis of t1/2 of LNG. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 21: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours; Day 22: 24 hours; Day 23: 48 hours and Day 24: 72 hours

Outcome Measure Data

Analysis Population Description
PK Population. Only those participants with data available at specified time points were analyzed.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 4
Geometric Mean (Geometric Coefficient of Variation) [Hours]
30.100
(4.2)
23. Secondary Outcome
Title Period 1: Tmax of LNG
Description Blood samples were collected at indicated time points for the analysis of Tmax of LNG. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 10: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours and Day 11: 24 hours

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Median (Full Range) [Hours]
2.000
24. Secondary Outcome
Title Period 2: Tmax of LNG
Description Blood samples were collected at indicated time points for the analysis of Tmax of LNG. PK parameters were calculated by standard non-compartmental analysis.
Time Frame Day 21: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 7, 12 hours; Day 22: 24 hours; Day 23: 48 hours and Day 24: 72 hours

Outcome Measure Data

Analysis Population Description
PK Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Median (Full Range) [Hours]
2.000
25. Secondary Outcome
Title Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAE) (Treatment Period)
Description An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. Safety Population comprised of all participants who received at least one dose of study medication.
Time Frame Up to Day 25

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG) Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10. Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 23 21
Non-serious AE
5
21.7%
9
NaN
SAE
0
0%
0
NaN
26. Secondary Outcome
Title Number of Participants With Non-SAEs and SAE (Run-in Period)
Description An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before.
Time Frame From Day -3 to Day -1

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia - Run-in Period (Day -3 to Day -1)
Arm/Group Description Participants in Run-in period received Portia (0.03 mg EE/0.15 mg LNG) QD on Day -3 through Day -1.
Measure Participants 23
Non-serious AE
0
0%
SAE
0
0%
27. Secondary Outcome
Title Period 1: Change From Baseline in Clinical Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium and Blood Urea Nitrogen (BUN)
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and BUN. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Glucose
-0.217
(0.3567)
Cholesterol
-0.153
(0.3219)
Triglycerides
-0.049
(0.2231)
Anion gap
1.3
(1.66)
Calcium
0.039
(0.0626)
Carbon dioxide
-1.8
(1.30)
Chloride
0.1
(1.82)
Phosphate
-0.030
(0.1056)
Potassium
-0.03
(0.343)
Sodium
-0.3
(2.12)
BUN
-0.180
(0.5956)
28. Secondary Outcome
Title Period 2: Change From Baseline in Clinical Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium and BUN
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and BUN. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Glucose, Day 21
-0.141
(0.2553)
Glucose, Day 24
0.084
(0.2043)
Cholesterol, Day 21
-0.161
(0.2891)
Cholesterol, Day 24
0.075
(0.4580)
Triglycerides, Day 21
-0.008
(0.1524)
Triglycerides, Day 24
-0.066
(0.1786)
Anion gap, Day 21
-1.5
(1.12)
Anion gap, Day 24
-0.6
(1.80)
Calcium, Day 21
-0.034
(0.0546)
Calcium, Day 24
0.000
(0.0643)
Carbon dioxide, Day 21
0.7
(1.16)
Carbon dioxide, Day 24
1.6
(0.87)
Chloride, Day 21
-0.6
(1.06)
Chloride, Day 24
0.5
(1.33)
Phosphate, Day 21
-0.074
(0.1073)
Phosphate, Day 24
-0.064
(0.0878)
Potassium, Day 21
-0.06
(0.253)
Potassium, Day 24
-0.02
(0.235)
Sodium, Day 21
-1.2
(1.03)
Sodium, Day 24
1.5
(1.66)
BUN, Day 21
-0.664
(0.5033)
BUN, Day 24
-0.568
(0.4591)
29. Secondary Outcome
Title Period 1: Change From Baseline in Clinical Chemistry Parameters: Plasma Albumin, Globulin and Protein
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including plasma albumin, globulin and protein. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Albumin
-0.1
(1.62)
Globulin
1.0
(1.60)
Protein
0.9
(2.94)
30. Secondary Outcome
Title Period 2: Change From Baseline in Clinical Chemistry Parameters: Plasma Albumin, Globulin and Protein
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including plasma albumin, globulin and protein. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Albumin, Day 21
-0.5
(1.46)
Albumin, Day 24
0.1
(2.52)
Globulin, Day 21
-0.4
(1.54)
Globulin, Day 24
0.8
(1.91)
Protein, Day 21
-0.9
(2.73)
Protein, Day 24
0.9
(4.31)
31. Secondary Outcome
Title Period 1: Change From Baseline in Clinical Chemistry Parameters: Plasma Amylase and Lipase
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including plasma amylase and lipase. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Amylase
-0.7
(7.83)
Lipase
2.1
(4.03)
32. Secondary Outcome
Title Period 2: Change From Baseline in Clinical Chemistry Parameters: Plasma Amylase and Lipase
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including plasma amylase and lipase. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Amylase, Day 21
3.2
(6.03)
Amylase, Day 24
5.2
(6.69)
Lipase, Day 21
1.8
(3.77)
Lipase, Day 24
1.6
(3.33)
33. Secondary Outcome
Title Period 1: Change From Baseline in Clinical Chemistry Parameters: Plasma Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Gamma Glutamyl Transferase (GGT)
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Plasma creatine kinase, lactate dehydrogenase, ALT, ALP, AST and GGT. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Creatine kinase
-3.6
(19.7)
lactate dehydrogenase
0.0
(11.76)
ALT
11.5
(24.80)
ALP
-3.9
(5.89)
AST
3.6
(9.74)
GGT
1.7
(8.36)
34. Secondary Outcome
Title Period 2: Change From Baseline in Clinical Chemistry Parameters: Plasma Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST and GGT
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Plasma creatine kinase, lactate dehydrogenase, ALT, ALP, AST and GGT. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Creatine kinase, Day 21
-1.6
(9.51)
Creatine kinase, Day 24
-1.7
(12.18)
Lactate dehydrogenase, Day 21
4.2
(10.61)
Lactate dehydrogenase, Day 24
8.4
(16.00)
ALT, Day 21
25.7
(24.80)
ALT, Day 24
34.5
(37.36)
ALP, Day 21
-1.1
(2.38)
ALP, Day 24
-1.9
(3.60)
AST, Day 21
10.1
(9.97)
AST, Day 24
12.6
(15.62)
GGT, Day 21
0.0
(1.73)
GGT, Day 24
0.1
(1.60)
35. Secondary Outcome
Title Period 1: Change From Baseline in Clinical Chemistry Parameters: Plasma Urate, Creatinine, Total Bilirubin and Direct Bilirubin
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Plasma urate, creatinine, total bilirubin and direct bilirubin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Urate
-18.0
(19.09)
Creatinine
0.93
(3.079)
Total bilirubin
-0.57
(1.638)
Direct bilirubin
-0.21
(0.467)
36. Secondary Outcome
Title Period 2: Change From Baseline in Clinical Chemistry Parameters: Plasma Urate, Creatinine, Total Bilirubin and Direct Bilirubin
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Plasma urate, creatinine, total bilirubin and direct bilirubin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Urate, Day 21
-45.2
(19.22)
Urate, Day 24
-34.7
(19.63)
Creatinine, Day 21
0.52
(2.852)
Creatinine, Day 24
1.29
(3.013)
Total bilirubin, Day 21
0.08
(1.000)
Total bilirubin, Day 24
0.12
(1.177)
Direct bilirubin, Day 21
0.07
(0.214)
Direct bilirubin, Day 24
0.15
(0.318)
37. Secondary Outcome
Title Period 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets
Description Blood samples were collected at indicated time points for the analysis of hematology parameters including Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Basophils
0.000
(0.0133)
Eosinophils
0.008
(0.0263)
Leukocytes
-0.02
(0.867)
Lymphocytes
0.086
(0.2168)
Monocytes
-0.012
(0.0760)
Neutrophils
-0.103
(0.7505)
Platelets
-1.6
(32.32)
38. Secondary Outcome
Title Period 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets
Description Blood samples were collected at indicated time points for the analysis of hematology parameters including Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Basophils, Day 21
0.001
(0.0130)
Basophils, Day 24
0.000
(0.0150)
Eosinophils, Day 21
0.001
(0.0209)
Eosinophils, Day 24
-0.005
(0.0414)
Leukocytes, Day 21
-0.43
(0.905)
Leukocytes, Day 24
-0.88
(0.901)
Lymphocytes, Day 21
-0.095
(0.2468)
Lymphocytes, Day 24
-0.101
(0.1617)
Monocytes, Day 21
-0.045
(0.0609)
Monocytes, Day 24
-0.064
(0.0676)
Neutrophils, Day 21
-0.285
(0.7448)
Neutrophils, Day 24
-0.708
(0.7253)
Platelets, Day 21
12.2
(31.07)
Platelets, Day 24
6.8
(27.18)
39. Secondary Outcome
Title Period 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
Description Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes mean corpuscular hemoglobin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Mean (Standard Deviation) [Picograms]
-0.09
(0.366)
40. Secondary Outcome
Title Period 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
Description Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes mean corpuscular hemoglobin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Day 21
-0.51
(0.394)
Day 24
-0.10
(0.377)
41. Secondary Outcome
Title Period 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
Description Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes mean corpuscular volume. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Mean (Standard Deviation) [Femtoliters]
-0.18
(0.657)
42. Secondary Outcome
Title Period 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
Description Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes mean corpuscular volume. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Day 21
-0.50
(0.516)
Day 24
0.04
(0.818)
43. Secondary Outcome
Title Period 1: Change From Baseline in Hematology Parameter: Erythrocytes
Description Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Mean (Standard Deviation) [10^12 cells per liter]
-0.010
(0.1287)
44. Secondary Outcome
Title Period 2: Change From Baseline in Hematology Parameter: Erythrocytes
Description Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Day 21
0.106
(0.1093)
Day 24
0.134
(0.1675)
45. Secondary Outcome
Title Period 1: Change From Baseline in Hematology Parameter: Hematocrit
Description Blood samples were collected at indicated time points for the analysis of hematology parameter hematocrit. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Mean (Standard Deviation) [Proportion of red blood cells in blood]
-0.0014
(0.01165)
46. Secondary Outcome
Title Period 2: Change From Baseline in Hematology Parameter: Hematocrit
Description Blood samples were collected at indicated time points for the analysis of hematology parameter hematocrit. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Day 21
0.0071
(0.01046)
Day 24
0.0118
(0.01711)
47. Secondary Outcome
Title Period 1: Change From Baseline in Hematology Parameter: Hemoglobin
Description Blood samples were collected at indicated time points for the analysis of hematology parameter hemoglobin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Mean (Standard Deviation) [Grams per liter]
-0.7
(3.74)
48. Secondary Outcome
Title Period 2: Change From Baseline in Hematology Parameter: Hemoglobin
Description Blood samples were collected at indicated time points for the analysis of hematology parameter hemoglobin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 17
Day 21
1.2
(3.63)
Day 24
3.8
(5.45)
49. Secondary Outcome
Title Period 1: Change From Baseline in Urine Concentration: Urine Specific Gravity
Description Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Mean (Standard Deviation) [Ratio]
0.0023
(0.00922)
50. Secondary Outcome
Title Period 2: Change From Baseline in Urine Concentration: Urine Specific Gravity
Description Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Day 21, n=18
-0.0028
(0.01150)
Day 24, n=17
-0.0021
(0.00888)
51. Secondary Outcome
Title Period 1: Change From Baseline in Urine Concentration: Urine Urobilinogen
Description Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Mean (Standard Deviation) [Micromoles per liter]
1.7666
(4.66388)
52. Secondary Outcome
Title Period 2: Change From Baseline in Urine Concentration: Urine Urobilinogen
Description Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Day 21, n=18
3.0098
(5.79402)
Day 24, n=17
0.0000
(4.78853)
53. Secondary Outcome
Title Period 1: Change From Baseline in Urine Concentration: Urine Potential of Hydrogen (pH)
Description Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Mean (Standard Deviation) [pH]
-0.22
(0.473)
54. Secondary Outcome
Title Period 2: Change From Baseline in Urine Concentration: Urine pH
Description Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Day 21, n=18
0.39
(0.583)
Day 24, n=17
0.24
(0.400)
55. Secondary Outcome
Title Period 1: Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate
Description Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Mean (Standard Deviation) [Beats per minute]
-0.8
(5.95)
56. Secondary Outcome
Title Period 2: Change From Baseline in ECG Mean Heart Rate
Description Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline is defined as the average of the triplicate predose assessments on Day 11. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 11, Pre-dose) and at Day 11: 2, 4, 6 hours, Day 15: 2, 4, 6 hours, Day 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Day 11: 2 hours, n=21
2.8
(5.17)
Day 11: 4 hours, n=21
-0.6
(4.79)
Day 11: 6 hours, n=21
6.7
(5.44)
Day 15: 2 hours, n=18
3.8
(6.23)
Day 15: 4 hours, n=18
1.7
(8.01)
Day 15: 6 hours, n=18
3.1
(7.10)
Day 21, n=18
3.7
(6.24)
Day 24, n=17
0.6
(4.42)
57. Secondary Outcome
Title Period 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF) Interval, and Bazett QT Correction Formula (QTcB) Interval
Description Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR interval, QRS duration, QT Interval, QTcF Interval and QTcB interval. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
PR interval
2.5
(8.65)
QRS duration
0.2
(5.01)
QT interval
-3.0
(11.32)
QTcF interval
-4.1
(8.18)
QTcB interval
-4.6
(11.80)
58. Secondary Outcome
Title Period 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF and QTcB Interval
Description Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline is defined as the average of the triplicate predose assessments on Day 11. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 11, Pre-dose) and at Day 11: 2, 4, 6 hours, Day 15: 2, 4, 6 hours, Day 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
PR interval, Day 11: 2 hours, n=21
0.3
(7.99)
PR interval, Day 11: 4 hours, n=21
1.9
(8.68)
PR interval, Day 11: 6 hours, n=21
-1.9
(9.45)
PR interval, Day 15: 2 hours, n=18
-1.7
(11.37)
PR interval, Day 15: 4 hours, n=18
-0.6
(10.03)
PR interval, Day 15: 6 hours, n=18
-2.3
(7.99)
PR interval, Day 21, n=18
1.7
(7.37)
PR interval, Day 24, n=17
2.1
(7.89)
QRS duration, Day 11: 2 hours, n=21
-2.2
(3.78)
QRS duration, Day 11: 4 hours, n=21
-0.7
(4.51)
QRS duration, Day 11: 6 hours, n=21
-0.3
(4.33)
QRS duration, Day 15: 2 hours, n=18
0.2
(3.78)
QRS duration, Day 15: 4 hours, n=18
0.1
(3.39)
QRS duration, Day 15: 6 hours, n=18
-0.9
(3.02)
QRS duration, Day 21, n=18
-0.4
(4.37)
QRS duration, Day 24, n=17
-0.4
(3.36)
QT interval, Day 11: 2 hours, n=21
-16.4
(8.23)
QT interval, Day 11: 4 hours, n=21
2.3
(10.78)
QT interval, Day 11: 6 hours, n=21
-11.7
(10.22)
QT interval, Day 15: 2 hours, n=18
-10.3
(10.09)
QT interval, Day 15: 4 hours, n=18
-0.4
(15.78)
QT interval, Day 15: 6 hours, n=18
2.2
(14.21)
QT interval, Day 21, n=18
-7.4
(13.77)
QT interval, Day 24, n=17
0.1
(10.06)
QTcF interval, Day 11: 2 hours, n=21
-11.5
(8.78)
QTcF interval, Day 11: 4 hours, n=21
1.4
(8.61)
QTcF interval, Day 11: 6 hours, n=21
1.3
(7.68)
QTcF interval, Day 15: 2 hours, n=18
-3.0
(6.15)
QTcF interval, Day 15: 4 hours, n=18
2.4
(9.71)
QTcF interval, Day 15: 6 hours, n=18
8.1
(9.07)
QTcF interval, Day 21, n=18
-0.3
(6.85)
QTcF interval, Day 24, n=17
1.4
(5.63)
QTcB interval, Day 11: 2 hours, n=21
-8.5
(13.11)
QTcB interval, Day 11: 4 hours, n=21
1.0
(11.57)
QTcB interval, Day 11: 6 hours, n=21
8.2
(11.84)
QTcB interval, Day 15: 2 hours, n=18
1.1
(11.25)
QTcB interval, Day 15: 4 hours, n=18
4.4
(15.09)
QTcB interval, Day 15: 6 hours, n=18
11.6
(12.41)
QTcB interval, Day 21, n=18
3.6
(9.20)
QTcB interval, Day 24, n=17
2.5
(7.67)
59. Secondary Outcome
Title Period 1: Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Description SBP and DBP were assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline is defined as the average of the triplicate pre-dose assessments. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
SBP
-4.3
(9.45)
DBP
-2.8
(7.84)
60. Secondary Outcome
Title Period 2: Change From Baseline in Vital Signs: SBP and DBP
Description SBP and DBP were assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline is defined as as the average of the triplicate pre-dose assessments. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 11, Pre-dose) and at Days 15, 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
SBP, Day 15, n=19
4.4
(6.51)
SBP, Day 21, n=18
1.6
(4.89)
SBP, Day 24, n=17
5.9
(6.95)
DBP, Day 15, n=19
3.0
(5.08)
DBP, Day 21, n=18
3.5
(3.38)
DBP, Day 24, n=17
6.1
(5.27)
61. Secondary Outcome
Title Period 1: Change From Baseline in Pulse Rate
Description Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline is defined as the average of the triplicate predose assessments. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Mean (Standard Deviation) [Beats per minute]
-0.2
(5.16)
62. Secondary Outcome
Title Period 2: Change From Baseline in Pulse Rate
Description Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline is defined as the average of the triplicate predose assessments. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 11, Pre-dose) and at Days 15, 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Day 15, n=19
5.8
(5.06)
Day 21, n=18
1.8
(5.71)
Day 24, n=17
0.9
(5.48)
63. Secondary Outcome
Title Period 1: Change From Baseline in Respiratory Rate
Description Respiratory rate was assessed at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Mean (Standard Deviation) [Breaths per minute]
2.3
(2.58)
64. Secondary Outcome
Title Period 2: Change From Baseline in Respiratory Rate
Description Respiratory rate was assessed at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 11, Pre-dose) and at Days 15, 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Day 15, n=19
1.7
(3.07)
Day 21, n=18
0.6
(2.15)
Day 24, n=17
0.9
(3.61)
65. Secondary Outcome
Title Period 1: Change From Baseline in Temperature
Description Temperature was assessed at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Mean (Standard Deviation) [Degree Celsius]
0.11
(0.452)
66. Secondary Outcome
Title Period 2: Change From Baseline in Temperature
Description Temperature was assessed at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time Frame Baseline (Day 11, Pre-dose) and at Days 15, 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Day 15, n=19
0.15
(0.434)
Day 21, n=18
0.02
(0.537)
Day 24, n=17
0.25
(0.505)
67. Secondary Outcome
Title Period 1: Absolute Values of Clinical Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium and BUN
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and BUN. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Glucose, Baseline
5.104
(0.5019)
Glucose, Day 10
4.887
(0.4616)
Cholesterol, Baseline
4.291
(0.9991)
Cholesterol, Day 10
4.138
(0.8322)
Triglycerides, Baseline
1.084
(0.5437)
Triglycerides, Day 10
1.035
(0.3940)
Anion gap, Baseline
9.9
(1.10)
Anion gap, Day 10
11.2
(1.44)
Calcium, Baseline
2.310
(0.0652)
Calcium, Day 10
2.349
(0.0593)
Carbon dioxide, Baseline
28.0
(1.17)
Carbon dioxide, Day 10
26.2
(1.44)
Chloride, Baseline
103.4
(1.41)
Chloride, Day 10
103.6
(1.83)
Phosphate, Baseline
1.165
(0.1000)
Phosphate, Day 10
1.135
(0.0881)
Potassium, Baseline
4.23
(0.288)
Potassium, Day 10
4.20
(0.265)
Sodium, Baseline
137.1
(1.24)
Sodium, Day 10
136.7
(1.57)
BUN, Baseline
3.659
(0.7512)
BUN, Day 10
3.478
(0.6738)
68. Secondary Outcome
Title Period 2: Absolute Values of Clinical Chemistry Parameters: Glucose, Cholesterol, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium and BUN
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Glucose, cholesterol, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium and BUN. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Glucose, Baseline, n=21
4.921
(0.4503)
Glucose, Day 21, n=17
4.769
(0.3922)
Glucose, Day 24, n=17
4.994
(0.3746)
Cholesterol, Baseline, n=21
4.104
(0.8622)
Cholesterol, Day 21, n=17
3.857
(0.8765)
Cholesterol, Day 24, n=17
4.093
(1.0474)
Triglycerides, Baseline, n=21
1.032
(0.4092)
Triglycerides, Day 21, n=17
1.080
(0.4505)
Triglycerides, Day 24, n=17
1.022
(0.5161)
Anion gap, Baseline, n=21
11.2
(1.48)
Anion gap, Day 21, n=17
9.6
(1.46)
Anion gap, Day 24, n=17
10.5
(1.42)
Calcium, Baseline, n=21
2.349
(0.0602)
Calcium, Day 21, n=17
2.314
(0.0706)
Calcium, Day 24, n=17
2.348
(0.0592)
Carbon dioxide, Baseline, n=21
26.0
(1.43)
Carbon dioxide, Day 21, n=17
26.7
(1.57)
Carbon dioxide, Day 24, n=17
27.6
(1.33)
Chloride, Baseline, n=21
103.7
(1.74)
Chloride, Day 21, n=17
103.0
(2.18)
Chloride, Day 24, n=17
104.1
(2.01)
Phosphate, Baseline, n=21
1.139
(0.0819)
Phosphate, Day 21, n=17
1.055
(0.0908)
Phosphate, Day 24, n=17
1.065
(0.0818)
Potassium, Baseline, n=21
4.18
(0.211)
Potassium, Day 21, n=17
4.12
(0.198)
Potassium, Day 24, n=17
4.16
(0.197)
Sodium, Baseline, n=21
136.9
(1.39)
Sodium, Day 21, n=17
135.4
(1.46)
Sodium, Day 24, n=17
138.1
(1.56)
BUN, Baseline, n=21
3.458
(0.6189)
BUN, Day 21, n=17
2.756
(0.4593)
BUN, Day 24, n=17
2.853
(0.5406)
69. Secondary Outcome
Title Period 1: Absolute Values of Clinical Chemistry Parameters: Plasma Albumin, Globulin and Protein
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including plasma albumin, globulin and protein. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Albumin, Baseline
42.0
(2.29)
Albumin, Day 10
42.0
(2.16)
Globulin, Baseline
28.8
(2.57)
Globulin, Day 10
29.8
(2.93)
Protein, Baseline
70.9
(4.06)
Protein, Day 10
71.8
(4.25)
70. Secondary Outcome
Title Period 2: Absolute Values of Clinical Chemistry Parameters: Plasma Albumin, Globulin and Protein
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including plasma albumin, globulin and protein. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Albumin, Baseline, n=21
41.9
(2.21)
Albumin, Day 21, n=17
41.4
(1.62)
Albumin, Day 24, n=17
42.0
(2.12)
Globulin, Baseline, n=21
29.7
(2.99)
Globulin, Day 21, n=17
29.2
(2.70)
Globulin, Day 24, n=17
30.4
(2.50)
Protein, Baseline, n=21
71.6
(4.40)
Protein, Day 21, n=17
70.5
(3.68)
Protein, Day 24, n=17
72.4
(3.97)
71. Secondary Outcome
Title Period 1: Absolute Values of Clinical Chemistry Parameters: Plasma Amylase and Lipase
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including plasma amylase and lipase. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Amylase, Baseline
49.4
(18.77)
Amylase, Day 10
48.7
(16.34)
Lipase, Baseline
18.8
(9.25)
Lipase, Day 10
20.9
(8.47)
72. Secondary Outcome
Title Period 2: Absolute Values of Clinical Chemistry Parameters: Plasma Amylase and Lipase
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including plasma amylase and lipase. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Amylase, Baseline, n=21
47.8
(16.79)
Amylase, Day 21, n=17
47.1
(17.93)
Amylase, Day 24, n=17
49.2
(18.38)
Lipase, Baseline, n=21
20.7
(8.83)
Lipase, Day 21, n=17
20.5
(7.40)
Lipase, Day 24, n=17
20.4
(8.16)
73. Secondary Outcome
Title Period 1: Absolute Values of Clinical Chemistry Parameters: Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST and GGT
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including creatine kinase, lactate dehydrogenase, ALT, ALP, AST and GGT. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Creatine kinase, Baseline
74.1
(25.37)
Creatine kinase, Day 10
70.5
(22.43)
Lactate dehydrogenase, Baseline
122.7
(21.78)
Lactate dehydrogenase, Day 10
122.7
(21.19)
ALT, Baseline
12.4
(6.45)
ALT, Day 10
23.9
(24.34)
ALP, Baseline
49.6
(12.00)
ALP, Day 10
45.7
(11.64)
AST, Baseline
14.2
(2.79)
AST, Day 10
17.7
(9.26)
GGT, Baseline
14.9
(5.62)
GGT, Day 10
16.7
(11.48)
74. Secondary Outcome
Title Period 2: Absolute Values of Clinical Chemistry Parameters: Plasma Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST and GGT
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Plasma creatine kinase, lactate dehydrogenase, ALT, ALP, AST and GGT. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Creatine kinase, Baseline, n=21
70.3
(23.37)
Creatine kinase, Day 21, n=17
69.4
(23.62)
Creatine kinase, Day 24, n=17
69.3
(22.46)
Lactate dehydrogenase, Baseline, n=21
123.3
(21.96)
Lactate dehydrogenase, Day 21, n=17
125.9
(24.85)
Lactate dehydrogenase, Day 24, n=17
130.1
(27.63)
ALT, Baseline, n=21
25.7
(27.34)
ALT, Day 21, n=17
42.2
(32.02)
ALT, Day 24, n=17
51.1
(45.07)
ALP, Baseline, n=21
44.9
(10.91)
ALP, Day 21, n=17
43.5
(10.46)
ALP, Day 24, n=17
42.6
(10.10)
AST, Baseline, n=21
17.7
(9.05)
AST, Day 21, n=17
25.4
(14.55)
AST, Day 24, n=17
27.9
(20.07)
GGT, Baseline, n=21
16.4
(11.60)
GGT, Day 21, n=17
13.0
(4.53)
GGT, Day 24, n=17
13.1
(4.45)
75. Secondary Outcome
Title Period 1: Absolute Values of Clinical Chemistry Parameters: Urate, Creatinine, Total Bilirubin and Direct Bilirubin
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Plasma urate, creatinine, total bilirubin and direct bilirubin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Urate, Baseline
260.4
(46.10)
Urate, Day 10
242.4
(46.30)
Creatinine, Baseline
67.75
(8.763)
Creatinine, Day 10
68.68
(9.846)
Total bilirubin, Baseline
8.35
(3.847)
Total bilirubin, Day 10
7.79
(3.480)
Direct bilirubin, Baseline
1.88
(0.871)
Direct bilirubin, Day 10
1.67
(0.701)
76. Secondary Outcome
Title Period 2: Absolute Values of Clinical Chemistry Parameters: Plasma Urate, Creatinine, Total Bilirubin and Direct Bilirubin
Description Blood samples were collected at indicated time points for the analysis of clinical chemistry parameters including Plasma urate, creatinine, total bilirubin and direct bilirubin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Urate, Baseline, n=21
240.3
(43.74)
Urate, Day 21, n=17
194.5
(35.17)
Urate, Day 24, n=17
205.1
(39.09)
Creatinine, Baseline, n=21
68.62
(10.637)
Creatinine, Day 21, n=17
66.92
(6.770)
Creatinine, Day 24, n=17
67.70
(7.456)
Total bilirubin, Baseline, n=21
7.98
(3.563)
Total bilirubin, Day 21, n=17
6.94
(1.600)
Total bilirubin, Day 24, n=17
6.99
(2.323)
Direct bilirubin, Baseline, n=21
1.72
(0.699)
Direct bilirubin, Day 21, n=17
1.56
(0.498)
Direct bilirubin, Day 24, n=17
1.64
(0.592)
77. Secondary Outcome
Title Period 1: Absolute Values of Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets
Description Blood samples were collected at indicated time points for the analysis of hematology parameters including Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Basophils, Baseline
0.038
(0.0239)
Basophils, Day 10
0.038
(0.0177)
Eosinophils, Baseline
0.103
(0.0555)
Eosinophils, Day 10
0.111
(0.0606)
Leukocytes, Baseline
6.23
(1.626)
Leukocytes, Day 10
6.21
(1.329)
Lymphocytes, Baseline
1.730
(0.3832)
Lymphocytes, Day 10
1.816
(0.3399)
Monocytes, Baseline
0.460
(0.1238)
Monocytes, Day 10
0.448
(0.1144)
Neutrophils, Baseline
3.905
(1.2865)
Neutrophils, Day 10
3.802
(1.1472)
Platelets, Baseline
284.4
(36.78)
Platelets, Day 10
282.8
(45.94)
78. Secondary Outcome
Title Period 2: Absolute Values of Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets
Description Blood samples were collected at indicated time points for the analysis of hematology parameters including Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Basophils, Baseline, n=21
0.039
(0.0184)
Basophils, Day 21, n=17
0.039
(0.0183)
Basophils, Day 24, n=17
0.038
(0.0142)
Eosinophils, Baseline, n=21
0.115
(0.0622)
Eosinophils, Day 21, n=17
0.118
(0.0631)
Eosinophils, Day 24, n=17
0.112
(0.0645)
Leukocytes, Baseline, n=21
6.20
(1.391)
Leukocytes, Day 21, n=17
5.86
(1.183)
Leukocytes, Day 24, n=17
5.41
(1.080)
Lymphocytes, Baseline, n=21
1.790
(0.3089)
Lymphocytes, Day 21, n=17
1.715
(0.3349)
Lymphocytes, Day 24, n=17
1.710
(0.2207)
Monocytes, Baseline, n=21
0.446
(0.1186)
Monocytes, Day 21, n=17
0.409
(0.0942)
Monocytes, Day 24, n=17
0.391
(0.0924)
Neutrophils, Baseline, n=21
3.811
(1.2013)
Neutrophils, Day 21, n=17
3.587
(1.0893)
Neutrophils, Day 24, n=17
3.165
(0.9633)
Platelets, Baseline, n=21
282.2
(46.73)
Platelets, Day 21, n=17
296.8
(50.45)
Platelets, Day 24, n=17
291.4
(42.75)
79. Secondary Outcome
Title Period 1: Absolute Values of Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
Description Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes mean corpuscular hemoglobin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Baseline
29.70
(2.010)
Day 10
29.62
(2.228)
80. Secondary Outcome
Title Period 2: Absolute Values of Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
Description Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes mean corpuscular hemoglobin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Baseline, n=21
29.92
(2.068)
Day 21, n=17
29.72
(1.779)
Day 24, n=17
30.12
(1.867)
81. Secondary Outcome
Title Period 1: Absolute Values of Hematology Parameter: Erythrocytes Mean Corpuscular Volume
Description Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes mean corpuscular volume. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Baseline
87.83
(5.060)
Day 10
87.65
(4.991)
82. Secondary Outcome
Title Period 2: Absolute Values of Hematology Parameter: Erythrocytes Mean Corpuscular Volume
Description Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes mean corpuscular volume. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Baseline, n=21
88.16
(4.889)
Day 21, n=17
88.39
(4.293)
Day 24, n=17
88.92
(4.278)
83. Secondary Outcome
Title Period 1: Absolute Values of Hematology Parameter: Erythrocytes
Description Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Baseline
4.316
(0.3113)
Day 10
4.306
(0.3008)
84. Secondary Outcome
Title Period 2: Absolute Values of Hematology Parameter: Erythrocytes
Description Blood samples were collected at indicated time points for the analysis of hematology parameter erythrocytes. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Baseline, n=21
4.308
(0.3103)
Day 21, n=17
4.356
(0.2518)
Day 24, n=17
4.383
(0.2998)
85. Secondary Outcome
Title Period 1: Absolute Values of Hematology Parameter: Hematocrit
Description Blood samples were collected at indicated time points for the analysis of hematology parameter hematocrit. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Baseline
0.3783
(0.02759)
Day 10
0.3769
(0.02467)
86. Secondary Outcome
Title Period 2: Absolute Values of Hematology Parameter: Hematocrit
Description Blood samples were collected at indicated time points for the analysis of hematology parameter hematocrit. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Baseline, n=21
0.3791
(0.02457)
Day 21, n=17
0.3848
(0.02650)
Day 24, n=17
0.3895
(0.02969)
87. Secondary Outcome
Title Period 1: Absolute Values of Hematology Parameter: Hemoglobin
Description Blood samples were collected at indicated time points for the analysis of hematology parameter hemoglobin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Baseline
128.0
(10.06)
Day 10
127.2
(9.29)
88. Secondary Outcome
Title Period 2: Absolute Values of Hematology Parameter: Hemoglobin
Description Blood samples were collected at indicated time points for the analysis of hematology parameter hemoglobin. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Baseline, n=21
128.5
(8.61)
Day 21, n=17
129.5
(10.22)
Day 24, n=17
132.1
(11.23)
89. Secondary Outcome
Title Period 1: Absolute Values of Urine Concentration: Urine Specific Gravity
Description Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Baseline
1.0136
(0.00693)
Day 10
1.0159
(0.00766)
90. Secondary Outcome
Title Period 2: Absolute Values of Urine Concentration: Urine Specific Gravity
Description Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Baseline, n=21
1.0162
(0.00792)
Day 21, n=18
1.0134
(0.00982)
Day 24, n=17
1.0139
(0.00807)
91. Secondary Outcome
Title Period 1: Absolute Values of Urine Concentration: Urine Urobilinogen
Description Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Baseline
3.3860
(0.00000)
Day 10
5.1526
(4.66388)
92. Secondary Outcome
Title Period 2: Absolute Values of Urine Concentration: Urine Urobilinogen
Description Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Baseline, n=21
5.3209
(4.85645)
Day 21, n=18
7.9007
(6.56981)
Day 24, n=17
4.1827
(3.28490)
93. Secondary Outcome
Title Period 1: Absolute Values of Urine Concentration: Urine pH
Description Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Baseline
6.09
(0.468)
Day 10
5.87
(0.310)
94. Secondary Outcome
Title Period 2: Absolute Values of Urine Concentration: Urine pH
Description Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Baseline, n=21
5.88
(0.312)
Day 21, n=18
6.28
(0.428)
Day 24, n=17
6.12
(0.219)
95. Secondary Outcome
Title Period 1: Number of Participants With Abnormal Urinalysis Parameters Using Dipstick Method.
Description The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters (ketones, glucose, bilirubin, occult blood, nitrite and blood protein) can be read as positive, trace, 1+, 2+, 3+ and 4+ indicating proportional concentrations in the urine sample. Only participants with abnormal findings for urinalysis at any visit has been presented.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Urine Ketone, Day 10, Trace
1
4.3%
Urine Ketone, Day 10, 1+
1
4.3%
Urine leukocyte esterase, Day 10, 1+
2
8.7%
Urine Nitrite, Baseline, Positive
1
4.3%
Urine occult blood, Baseline, 1+
1
4.3%
Urine occult blood, Baseline, 2+
2
8.7%
Urine occult blood, Baseline, 3+
2
8.7%
Urine occult blood, Day 10, Trace
1
4.3%
Urine occult blood, Day 10, 1+
2
8.7%
Urine occult blood, Day 10, 3+
1
4.3%
Urine protein, Day 10, Trace
1
4.3%
96. Secondary Outcome
Title Period 2: Number of Participants With Abnormal Urinalysis Parameters Using Dipstick Method.
Description The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters (ketones, glucose, bilirubin, occult blood, nitrite and blood protein) can be read as positive, trace, 1+, 2+, 3+ and 4+ indicating proportional concentrations in the urine sample. Only participants with abnormal findings for urinalysis at any visit has been presented.
Time Frame Baseline (Day 10) and at Days 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Urine Ketone, Baseline, Trace
1
4.3%
Urine Ketone, Baseline, 1+
1
4.3%
Urine Ketone, Day 21, Trace
1
4.3%
Urine Ketone, Day 24, 2+
1
4.3%
Urine leukocyte esterase, Baseline, 1+
2
8.7%
Urine leukocyte esterase, Day 21, 1+
1
4.3%
Urine Nitrite, Day 21, Positive
1
4.3%
Urine Nitrite, Day 24, Positive
1
4.3%
Urine occult blood, Baseline, Trace
1
4.3%
Urine occult blood, Baseline, 1+
2
8.7%
Urine occult blood, Baseline, 3+
1
4.3%
Urine occult blood, Day 21, Trace
3
13%
Urine occult blood, Day 21, 3+
1
4.3%
Urine occult blood, Day 24, Trace
1
4.3%
Urine occult blood, Day 24, 1+
2
8.7%
Urine occult blood, Day 24, 2+
1
4.3%
Urine occult blood, Day 24, 3+
1
4.3%
Urine Protein, Baseline, Trace
1
4.3%
97. Secondary Outcome
Title Period 1: Absolute Values of ECG Mean Heart Rate
Description Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Baseline
67.9
(10.09)
Day 10
67.0
(7.07)
98. Secondary Outcome
Title Period 2: Absolute Values of ECG Mean Heart Rate
Description Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline is defined as the average of the triplicate predose assessments on Day 11.
Time Frame Baseline (Day 11, Pre-dose) and at Day 11: 2, 4, 6 hours, Day 15: 2, 4, 6 hours, Day 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Baseline, n=21
64.6
(8.49)
Day 11: 2 hours, n=21
67.4
(7.89)
Day 11: 4 hours, n=21
64.0
(6.73)
Day 11: 6 hours, n=21
71.3
(7.59)
Day 15: 2 hours, n=18
67.9
(9.42)
Day 15: 4 hours, n=18
65.8
(9.53)
Day 15: 6 hours, n=18
67.2
(8.80)
Day 21, n=18
67.8
(7.72)
Day 24, n=17
64.5
(7.41)
99. Secondary Outcome
Title Period 1: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval, and QTcB Interval
Description Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR interval, QRS duration, QT Interval, QTcF Interval and QTcB interval. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
PR interval, Baseline
156.1
(20.37)
PR interval, Day 10
158.6
(19.93)
QRS duration, Baseline
85.7
(9.86)
QRS duration, Day 10
85.9
(8.81)
QT interval, Baseline
389.8
(22.39)
QT interval, Day 10
386.8
(19.95)
QTcF interval, Baseline
404.7
(13.56)
QTcF interval, Day 10
400.6
(12.77)
QTcB interval, Baseline
412.0
(18.41)
QTcB interval, Day 10
407.4
(14.28)
100. Secondary Outcome
Title Period 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF and QTcB Interval
Description Twelve-lead ECGs were performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR Interval, QRS Duration, QT Interval, QTcF and QTcB Interval. Baseline is defined as the average of the triplicate predose assessments on Day 11.
Time Frame Baseline (Day 11, Pre-dose) and at Day 11- 2, 4, 6 hours, Day 15- 2, 4, 6 hours, Day 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
PR interval, Baseline, n=21
159.1
(18.22)
PR interval, Day 11: 2 hours, n=21
159.4
(19.73)
PR interval, Day 11: 4 hours, n=21
161.0
(18.73)
PR interval, Day 11: 6 hours, n=21
157.2
(20.08)
PR interval, Day 15: 2 hours, n=18
158.7
(21.29)
PR interval, Day 15: 4 hours, n=18
159.8
(17.11)
PR interval, Day 15: 6 hours, n=18
158.1
(17.46)
PR interval, Day 21, n=18
162.1
(18.06)
PR interval, Day 24, n=17
162.8
(15.26)
QRS duration, Baseline, n=21
85.5
(7.40)
QRS duration, Day 11: 2 hours, n=21
83.3
(6.57)
QRS duration, Day 11: 4 hours, n=21
84.9
(10.17)
QRS duration, Day 11: 6 hours, n=21
85.2
(8.05)
QRS duration, Day 15: 2 hours, n=18
84.8
(6.68)
QRS duration, Day 15: 4 hours, n=18
84.6
(8.33)
QRS duration, Day 15: 6 hours, n=18
83.6
(8.44)
QRS duration, Day 21, n=18
84.1
(9.46)
QRS duration, Day 24, n=17
83.5
(8.60)
QT interval, Baseline, n=21
394.2
(22.09)
QT interval, Day 11: 2 hours, n=21
377.8
(20.18)
QT interval, Day 11: 4 hours, n=21
396.5
(21.88)
QT interval, Day 11: 6 hours, n=21
382.5
(22.01)
QT interval, Day 15: 2 hours, n=18
382.9
(18.90)
QT interval, Day 15: 4 hours, n=18
392.8
(24.36)
QT interval, Day 15: 6 hours, n=18
395.3
(25.60)
QT interval, Day 21, n=18
385.7
(25.68)
QT interval, Day 24, n=17
394.2
(22.25)
QTcF interval, Baseline, n=21
403.2
(12.93)
QTcF interval, Day 11: 2 hours, n=21
391.8
(10.63)
QTcF interval, Day 11: 4 hours, n=21
404.6
(12.78)
QTcF interval, Day 11: 6 hours, n=21
404.5
(14.13)
QTcF interval, Day 15: 2 hours, n=18
398.2
(11.51)
QTcF interval, Day 15: 4 hours, n=18
403.6
(11.73)
QTcF interval, Day 15: 6 hours, n=18
409.3
(12.19)
QTcF interval, Day 21, n=18
400.8
(13.69)
QTcF interval, Day 24, n=17
403.0
(12.02)
QTcB interval, Baseline, n=21
407.2
(16.45)
QTcB interval, Day 11: 2 hours, n=21
398.7
(12.38)
QTcB interval, Day 11: 4 hours, n=21
408.2
(12.46)
QTcB interval, Day 11: 6 hours, n=21
415.4
(15.09)
QTcB interval, Day 15: 2 hours, n=18
405.5
(16.82)
QTcB interval, Day 15: 4 hours, n=18
408.8
(13.73)
QTcB interval, Day 15: 6 hours, n=18
415.9
(11.36)
QTcB interval, Day 21, n=18
407.9
(11.29)
QTcB interval, Day 24, n=17
407.2
(12.99)
101. Secondary Outcome
Title Period 1: Absolute Values of Vital Signs: SBP and DBP
Description SBP and DBP were assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline is defined as the average of the triplicate predose assessments on Day 11.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
SBP, Baseline
115.7
(8.50)
SBP, Day 10
111.4
(12.58)
DBP, Baseline
71.9
(8.87)
DBP, Day 10
69.1
(8.71)
102. Secondary Outcome
Title Period 2: Absolute Values of Vital Signs: SBP and DBP
Description SBP and DBP were assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 11, Pre-dose) and at Days 15, 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
SBP, Baseline, n=21
110.0
(8.24)
SBP, Day 15, n=19
113.3
(6.63)
SBP, Day 21, n=18
110.1
(5.22)
SBP, Day 24, n=17
114.5
(7.00)
DBP, Baseline, n=21
64.6
(7.69)
DBP, Day 15, n=19
66.7
(5.85)
DBP, Day 21, n=18
67.4
(6.01)
DBP, Day 24, n=17
69.7
(6.63)
103. Secondary Outcome
Title Period 1: Absolute Values of Pulse Rate
Description Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Baseline
70.1
(10.20)
Day 10
70.0
(9.28)
104. Secondary Outcome
Title Period 2: Absolute Values of Pulse Rate
Description Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 11, Pre-dose) and at Days 15, 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Baseline, n=21
69.2
(12.19)
Day 15, n=19
73.5
(8.62)
Day 21, n=18
69.4
(7.11)
Day 24, n=17
68.4
(7.63)
105. Secondary Outcome
Title Period 1: Absolute Values of Respiratory Rate
Description Respiratory rate was assessed indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Baseline
13.6
(2.56)
Day 10
15.8
(2.33)
106. Secondary Outcome
Title Period 2: Absolute Values of Respiratory Rate
Description Respiratory rate was assessed indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 11, Pre-dose) and at Days 15, 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Baseline, n=21
13.2
(2.41)
Day 15, n=19
15.1
(2.93)
Day 21, n=18
14.1
(1.88)
Day 24, n=17
14.5
(2.60)
107. Secondary Outcome
Title Period 1: Absolute Values of Temperature
Description Temperature was assessed at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 1, Pre-dose) and at Day 10

Outcome Measure Data

Analysis Population Description
Safety Population.
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)
Arm/Group Description Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10.
Measure Participants 23
Baseline
36.66
(0.487)
Day 10
36.77
(0.335)
108. Secondary Outcome
Title Period 2: Absolute Values of Temperature
Description Temperature was assessed at indicated time-points. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits, within each treatment.
Time Frame Baseline (Day 11, Pre-dose) and at Days 15, 21 and 24

Outcome Measure Data

Analysis Population Description
Safety Population. Only those participants with data available at specified time points were analyzed (represented by n=X in the category titles).
Arm/Group Title Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
Measure Participants 21
Baseline, n=21
36.60
(0.434)
Day 15, n=19
36.75
(0.391)
Day 21, n=18
36.59
(0.424)
Day 24, n=17
36.82
(0.481)

Adverse Events

Time Frame Non-serious AEs and SAEs were collected from Day -3 to Day -1 in Run-in period and up to Day 25 in Treatment period.
Adverse Event Reporting Description Non-serious AEs and SAEs were reported for the safety population which comprised of all participants who received at least one dose of study medication.
Arm/Group Title Portia - Run-in Period (Day -3 to Day -1) Portia (0.3 mg EE/ 0.15 mg LNG) Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Arm/Group Description Participants in Run-in period received Portia (0.03 mg EE/0.15 mg LNG) QD on Day -3 through Day -1. Participants in period 1 received Portia (0.3 mg of EE and 0.15 mg LNG) QD on Day 1 through Day 10. Participants in treatment period 2 were co-administered with GSK3640254 200 mg QD along with Portia from Day 11 through Day 21.
All Cause Mortality
Portia - Run-in Period (Day -3 to Day -1) Portia (0.3 mg EE/ 0.15 mg LNG) Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 0/23 (0%) 0/23 (0%) 0/21 (0%)
Serious Adverse Events
Portia - Run-in Period (Day -3 to Day -1) Portia (0.3 mg EE/ 0.15 mg LNG) Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 0/23 (0%) 0/23 (0%) 0/21 (0%)
Other (Not Including Serious) Adverse Events
Portia - Run-in Period (Day -3 to Day -1) Portia (0.3 mg EE/ 0.15 mg LNG) Portia (0.3 mg EE/ 0.15 mg LNG)+GSK3640254
Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 0/23 (0%) 5/23 (21.7%) 9/21 (42.9%)
Gastrointestinal disorders
Abdominal pain 0/23 (0%) 1/23 (4.3%) 1/21 (4.8%)
Diarrhoea 0/23 (0%) 0/23 (0%) 2/21 (9.5%)
Infrequent bowel movements 0/23 (0%) 0/23 (0%) 2/21 (9.5%)
Investigations
Transaminases increased 0/23 (0%) 4/23 (17.4%) 1/21 (4.8%)
Nervous system disorders
Headache 0/23 (0%) 0/23 (0%) 4/21 (19%)
Reproductive system and breast disorders
Metrorrhagia 0/23 (0%) 2/23 (8.7%) 1/21 (4.8%)
Skin and subcutaneous tissue disorders
Pruritus 0/23 (0%) 0/23 (0%) 2/21 (9.5%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.

Results Point of Contact

Name/Title GSK Response Center
Organization ViiV Healthcare
Phone 866-435-7343
Email GSKClinicalSupportHD@gsk.com
Responsible Party:
ViiV Healthcare
ClinicalTrials.gov Identifier:
NCT03984825
Other Study ID Numbers:
  • 208135
First Posted:
Jun 13, 2019
Last Update Posted:
Aug 27, 2020
Last Verified:
Aug 1, 2020